Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population

2000 ◽  
Vol 56 (6-7) ◽  
pp. 495-499 ◽  
Author(s):  
S. Sihvo ◽  
T. Klaukka ◽  
J. Martikainen ◽  
E. Hemminki
Keyword(s):  
Drug Use ◽  
Drug Interactions ◽  
Prescription Drug ◽  
Adult Population ◽  
Over The Counter ◽  
Clinically Significant

Prevalence and temporal trends of prescription drug use in cancer survivors: A population study, 2001 to 2016.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12023-12023
Author(s):  
Elisa Liu ◽  
Sylvia Christine Kurz ◽  
Jiyoung Ahn ◽  
Erik P. Sulman
Keyword(s):  
Drug Use ◽  
Cancer Survivors ◽  
Prescription Drug ◽  
Adult Population ◽  
Temporal Trends ◽  
Drug Usage ◽  
Cross Sectional ◽  
Prescription Drug Use ◽  
Financial Burdens

12023 Background: The burden of prescription drug use is higher in cancer survivors than the general population. We examined the prevalence and temporal trends of prescription drug use among cancer survivors, with an emphasis on central nervous system (CNS) active medications used to manage long-term cancer sequelae. Methods: Adult respondents with (n=3207) and without (n=40,440) a prior cancer diagnosis from 8 cycles (2001-2016) of the National Health and Nutritional Examinational Survey (NHANES) were evaluated for prescription drug usage. Cross-sectional analyses and temporal trends across cycles were evaluated and weighted to represent the US adult population. Results: Cancer survivors report higher rates of prescription drug usage (85.1% vs 54.3%, p<0.001, and 75.8%, p<0.001) and polypharmacy (27.8% vs 10.7%, p<0.001, and 22.7%, p<0.001) than both unadjusted and age-adjusted controls. Younger survivors report greater usage of CNS (36.8% vs 13.1%, p<0.001), psychotherapeutic (18.4% vs 7.7%, p<0.001), hormonal agents (19.1% vs 10.1%, p=0.003), and gastrointestinal (10.7% vs 4.7%, p=0.02) than controls, while differences are attenuated in older cohorts. Among broad drug categories, the usage of cardiovascular (p-trend<0.001), metabolic (p-trend<0.001), and immunologic agents (p-trend=0.01) has increased. Among CNS active subclasses, the usage of anticonvulsants (p-trend<0.001), anxiolytics (p-trend =0.02), narcotics (p-trend=0.02) and GABA analogs (p-trend<0.001) has increased. When comparing respondents with and without a history of cancer, the increased usage of anti-depressant prescription medications (18.3% vs 1.5% p<0.001), including SSRIs (11.2% vs 1.0%, p<0.001), SSNRIs (3.5% vs 0.3%, p<0.001), tricyclics (2.8% vs 0.1%, p<0.001), among cancer survivors was disproportionate compared to the increased proportion of positive depression screens (9.2% vs 7.0%, p=0.006). Conclusions: Cancer survivors report higher prescription drug use for both chronic conditions and late effects of cancer. The usage of CNS active medications, many of which are used on and off label for their pain management properties, has increased. The higher rates of pharmaceutical use may result in unanticipated long-term toxicities and financial burdens.

Patterns of prescription drug use and incidence of drug-drug interactions in patients reporting to medical emergency

2011 ◽  
Vol 27 (2) ◽  
pp. 231-237 ◽  
Author(s):  
Puneet Dhamija ◽  
Dipika Bansal ◽  
Anand Srinivasan ◽  
Ashish Bhalla ◽  
Debasish Hota ◽  
...  
Keyword(s):  
Drug Use ◽  
Drug Interactions ◽  
Prescription Drug ◽  
Medical Emergency ◽  
Prescription Drug Use

Transition of Products From Prescription to Over the Counter: The H2 Antagonists

1992 ◽  
Vol 5 (1) ◽  
pp. 22-30 ◽  
Author(s):  
Edward J. Drea
Keyword(s):  
Clinical Trials ◽  
Drug Use ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Case Reports ◽  
Rational Selection ◽  
Over The Counter ◽  
H2 Antagonists ◽  
Reporting Systems

In general, the histamine type-2 receptor antagonists (H2RA) enjoy an enviable record of safety. These agents, notably cimetidine, have been studied extensively in clinical trials, case reports, and worldwide drug use reporting systems. Of the available agents (cimetidine, famotidine, nizatidine, and ranitidine) several similarities exist from compound to compound and use data to support that each of the agents is equally safe and efficacious in equipotent dosing. A review of H2RA pharmacology, pharmacokinetics, adverse effects, and drug interactions is included to provide the clinician with a basis for rational selection and use of an H2RA.

The Incidence of Mood Altering Drug Use and Abuse among Middle-Aged Women in Florida

1978 ◽  
Vol 8 (1) ◽  
pp. 9-17
Author(s):  
Timothy L. Shepherd ◽  
C. Edward Wotring ◽  
David Schmeling
Keyword(s):  
Drug Use ◽  
Prescription Drug ◽  
Prescription Drugs ◽  
Panel Study ◽  
Middle Aged ◽  
Over The Counter ◽  
Large Sample ◽  
Prescription Drug Use ◽  
Purposive Sample ◽  
At Home

This report presents some findings of two studies designed to examine the incidence of mood altering prescription drug use among middle-aged women in Florida. The first study was a panel study of a small purposive sample of middle-aged women. The second study utilized a large sample from four major population areas of Florida of women at home during the day. The use of mood altering prescription drugs such as barbiturates, amphetamines, tranquilizers and sedatives was examined as well as the use of over-the-counter non-prescription drugs.

Recreational Prescription Drug Use Among College Students

NASPA Journal ◽  
2006 ◽  
Vol 43 (1) ◽  
Author(s):  
Ethan A Kolek
Keyword(s):  
Drug Use ◽  
Prescription Drug ◽  
Undergraduate Students ◽  
Prescription Drugs ◽  
Drug Users ◽  
Research University ◽  
Future Research ◽  
Negative Consequences ◽  
Prescription Drug Use ◽  
Other Substances

The purpose of this study was to explore recreational prescription drug use among undergraduate students. Although anecdotal accounts on this subject abound, empirical research is extremely limited. Data from a survey of a random sample of 734 students at a large public research university in the Northeast were examined. Results indicate that a substantial proportion of students reported having used prescription drugs for recreational purposes in the year prior to survey administration. Recreational prescription drug use was positively associated with the use of other substances including alcohol. Recreational prescription drug users were also more likely than other drug users to report negative consequences as a result of their drug use. Implications for future research and for student affairs are discussed.

scholarly journals Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

2020 ◽  
Vol 75 (12) ◽  
pp. 3417-3424 ◽  
Author(s):  
Catherine Hodge ◽  
Fiona Marra ◽  
Catia Marzolini ◽  
Alison Boyle ◽  
Sara Gibbons ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Herbal Medicines ◽  
Qt Prolongation ◽  
Critically Ill Patient ◽  
Experimental Drugs ◽  
Mesh Terms ◽  
Experimental Therapies ◽  
Clinically Significant ◽  
Novel Coronavirus

Abstract As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug–drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for ‘COVID-19’, ‘2019-nCoV’, ‘2019 novel coronavirus’ and ‘SARS-CoV-2’. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms ‘COVID-19’, ‘Comorbidity’ and ‘Epidemiological Factors’. Potential drug–drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug–drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: caution; RED: serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug–drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug–drug interaction resource to facilitate medication review for the critically ill patient.

Sign in / Sign up

Export Citation Format

Share Document